These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38746089)

  • 1. MT-125 Inhibits Non-Muscle Myosin IIA and IIB, Synergizes with Oncogenic Kinase Inhibitors, and Prolongs Survival in Glioblastoma.
    Kenchappa R; Radnai L; Young EJ; Zarco N; Lin L; Dovas A; Meyer CT; Haddock A; Hall A; Canoll P; Cameron MD; Nagaiah NK; Rumbaugh G; Griffin PR; Kamenecka TM; Miller CA; Rosenfeld SS
    bioRxiv; 2024 Apr; ():. PubMed ID: 38746089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential.
    Radnai L; Young EJ; Kikuti C; Hafenbreidel M; Stremel RF; Lin L; Toth K; Pasetto P; Jin X; Patel A; Conlon M; Briggs S; Heidsieck L; Sweeney HL; Sellers J; Krieger-Burke T; Martin WH; Sisco J; Young S; Pearson P; Rumbaugh G; Araldi GL; Duddy SK; Cameron MD; Surman M; Houdusse A; Griffin PR; Kamenecka TM; Miller CA
    bioRxiv; 2024 Oct; ():. PubMed ID: 39416074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmuscle myosin IIA and IIB differently suppress microtubule growth to stabilize cell morphology.
    Sato Y; Kamijo K; Tsutsumi M; Murakami Y; Takahashi M
    J Biochem; 2020 Jan; 167(1):25-39. PubMed ID: 31599953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.
    D'Amico R; Lei L; Kennedy BC; Sisti J; Ebiana V; Crisman C; Christensen JG; Gil O; Rosenfeld SS; Canoll P; Bruce JN
    Neurol Res; 2012 Apr; 34(3):252-61. PubMed ID: 22449730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
    Cam M; Charan M; Welker AM; Dravid P; Studebaker AW; Leonard JR; Pierson CR; Nakano I; Beattie CE; Hwang EI; Kambhampati M; Nazarian J; Finlay JL; Cam H
    Neuro Oncol; 2020 Mar; 22(3):345-356. PubMed ID: 31763674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A functional role of S100A4/non-muscle myosin IIA axis for pro-tumorigenic vascular functions in glioblastoma.
    Inukai M; Yokoi A; Ishizuka Y; Hashimura M; Matsumoto T; Oguri Y; Nakagawa M; Ishibashi Y; Ito T; Kumabe T; Saegusa M
    Cell Commun Signal; 2022 Apr; 20(1):46. PubMed ID: 35392912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
    Song K; Yuan Y; Lin Y; Wang YX; Zhou J; Gai QJ; Zhang L; Mao M; Yao XX; Qin Y; Lu HM; Zhang X; Cui YH; Bian XW; Zhang X; Wang Y
    Am J Cancer Res; 2018; 8(5):792-809. PubMed ID: 29888103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner.
    Picariello HS; Kenchappa RS; Rai V; Crish JF; Dovas A; Pogoda K; McMahon M; Bell ES; Chandrasekharan U; Luu A; West R; Lammerding J; Canoll P; Odde DJ; Janmey PA; Egelhoff T; Rosenfeld SS
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15550-15559. PubMed ID: 31235578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential contributions of nonmuscle myosin IIA and IIB to cytokinesis in human immortalized fibroblasts.
    Yamamoto K; Otomo K; Nemoto T; Ishihara S; Haga H; Nagasaki A; Murakami Y; Takahashi M
    Exp Cell Res; 2019 Mar; 376(1):67-76. PubMed ID: 30711568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
    Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.
    Lescarbeau RS; Lei L; Bakken KK; Sims PA; Sarkaria JN; Canoll P; White FM
    Mol Cancer Ther; 2016 Jun; 15(6):1332-43. PubMed ID: 27196784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 17. A Novel Small-Molecule Inhibitor of MRCK Prevents Radiation-Driven Invasion in Glioblastoma.
    Birch JL; Strathdee K; Gilmour L; Vallatos A; McDonald L; Kouzeli A; Vasan R; Qaisi AH; Croft DR; Crighton D; Gill K; Gray CH; Konczal J; Mezna M; McArthur D; Schüttelkopf AW; McConnell P; Sime M; Holmes WM; Bower J; McKinnon HJ; Drysdale M; Olson MF; Chalmers AJ
    Cancer Res; 2018 Nov; 78(22):6509-6522. PubMed ID: 30279244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
    Kanai R; Wakimoto H; Martuza RL; Rabkin SD
    Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.